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Summary 
Interleukin  10 (I1:10) decreases production of 11:1, II:6,  and tumor necrosis factor c~ (TNF-ot) 
in vitro, and neutralization  of II:10 in mice leads to elevation of the same monokines.  We test 
here whether this monokine-suppressing property of I1:10 confers on it the capacity to protect 
mice from lipopolysaccharide-induced  shock,  a monokine-mediated  inflammatory reaction.  A 
single injection of 0.5-1/~g of recombinant murine IL-10 reproducibly protected BALB/c mice 
from a lethal intraperitoneal injection of endotoxin. This result was obtained whether the I1:10 
was administered concurrently with, or 30 min after the injection of endotoxin. The protective 
effect of IL-10 was reversed by prior injection of neutralizing anti-I1:10 antibodies, and correlated 
with a substantial decrease in endotoxin-induced TNF-ot release.  These data implicate IL-10 as 
a candidate for treatment of bacterial sepsis, and more generally as an effective antiinflammatory 
reagent. 
S 
evere bacterial infections can result in profound physiolo- 
gical changes including hypotension, fever, tissue necrosis, 
widespread organ dysfunction, and ultimately death. In the 
case of gram-negative bacteria, this toxicity is due to endo- 
toxin, a LPS component of the bacterial cell wall (1, 2). In- 
deed, injection of appropriate doses of LPS into rabbits, mice, 
and other animals produces changes that  are typical of the 
septic shock syndrome, thus yielding a simple animal model 
of this inflammatory reaction.  Endotoxin-induced  toxicity 
appears to be due to the release of TNF-ot and/or I1:1 from 
endotoxin-stimulated macrophages/monocytes, since animals 
can be protected from bacterial and endotoxin-induced shock 
by neutralization of these monokines, using either mAhs or 
a physiological I1:1  antagonist  termed IL-lra  (3,  4). 
IL-10 is a 35-kD protein produced as a result of immune 
activation by subpopulations of helper T cells (5, 6), B cells 
(7, 8), and macrophage/monocytes (9, 10). Its numerous in 
vitro properties (for reviews see references 11 and 12) include 
suppression of IFN-y production by helper T cells and NK 
cells (5, 13), growth costimulation of thymocytes, mast cells, 
and B cells (14-17),  and suppression of monokine produc- 
tion (9, 10, 18, 19). With respect to the latter property, IL-10 
profoundly suppresses the induced production of TNF-c~, I1: 
lot, I1:1B, IL-6, IL-8, and GM-CSF by human monocytes (9) 
and mouse peritoneal macrophages  (10).  In contrast,  11:10 
has no effect on constitutive expression of TGF-~/by mono- 
cytes (9) and actually upregulates monocyte production  of 
the IL-lra (20). These in vitro data are supported by in vivo 
experiments showing that neutralization of I1:10 using specific 
mAbs leads to elevated levels of circulating TNF-ot and I1:6 
in mice (11). We test here whether  the ability of I1:10  to 
suppress production  of TNF-o~ and I1:1  together  with  its 
ability to increase Iblra, renders this cytokine capable of pro- 
tecting  mice against  endotoxin-induced  shock. 
Materials and Methods 
Mice.  8-wk-old  BALB/c  female mice  were  obtained  from 
Simonsen Laboratories (Gilroy, CA).  Animals were kept in the 
DNAX Animal Facility for a consistent 2.5 d before experimenta- 
tion to help minimize  animal-to-animal variation. 
Reagents.  LPS from Escherichia coli serotype 0111:B4 was pur- 
chased from Sigma Immunochemicals (St. Louis, MO). Two sepa- 
rate preparations (designated batch No. 1 and batch  No. 2) pre- 
pared in an identical manner were used throughout  the entire study. 
Recombinant  murine  Ibl0 was expressed in E. coli and purified 
to  homogeneity and  high  sp  act  ('~1.75  x  106 U/mg)  after 
refolding using hydrophobic and ion exchange chromatography. 
The protein concentration  in the purified preparations was deter- 
mined by the extinction coef~cient of the protein (1 mg/ml = 0.36 
A2s0). This material contained <0.10 etl/mg protein of endotoxin, 
and remained stable at 4~  for at least 6 too. The specific activity 
of murine IL-10 was evaluated in the cytokine synthesis inhibition 
assay (5). Recombinant  IL-10 was diluted in PBS containing 0.1% 
BSA, and administered to mice at various concentrations in a total 
volume of 100/A. Neutralizing  antibody experiments utilized the 
2A5 rat IgG1 anti-mouse IL-10 mAb (21), or an isotype control 
antibody designated GLl13. 
Endotoxin-induced Shock.  Mice were injected intraperitoneally 
with 100/zl vol containing  doses of endotoxin ranging from 250 
to 425/~g. The dose-response curves of animal survival versus en- 
dotoxin dose using either of two different preparations of endo- 
toxin are shown in Table 1. From these data, the LD90 selected 
for LPS batch No. 1 and LPS batch No. 2 was 350/~g/mouse  and 
400/zg/mouse,  respectively. 
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a cytokine-specific ELISA, commercially available from Endogen, 
Inc. (Boston, MA). 
Results and Discussion 
To evaluate the effect of Ibl0 on lethal endotoxemia in 
mice, groups of 20 BALB/c mice were injected intraperitoneaUy 
with  100 ~1 containing  an LDg0 of LPS (between 350 and 
400/~g, depending on the batch ofendotoxin), together with 
an additional 100 #1 containing either PBS or varying amounts 
of recombinant murine IL-10. In seven independent  experi- 
ments of this type, mice were completely protected from death 
resulting from LPS-induced shock when either 0.5,  1.0,  or 
10 #g of IL-10 was administered to the animal concurrently 
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IL-10 protects mice from lethal endotoxemia. Six groups of 
20 BALB/c mice were injected intraperitoneally with 350/~g LPS, together 
with 100/~1 PBS (D) or an equivalent volume containing the following 
doses of purified recombinant murine Ibl0:0.05/~g (i), 0.1 #g (O), 
0.5/~g (O), 1.0 #g (e), or 10/~g (O). Death was monitored over the 
following 7 d. Similar results were obtained in six additional experiments 
(refer to Table 1). 
Table  1.  Survival of BALB/c Mice Injected Intraperitoneally 
with Different Amounts of Endotoxin 
LPS/mouse 
No.  survivors/total mice 
LPS batch no.  1  LPS batch no.  2 
~g 
250 
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300 
325 
350 
375 
400 
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Figure  2.  Anti-lbl0 antibodies neutralize the ability of IL-10 to pro- 
tect mice from lethal endotoxemia. Groups of 20 BALB/c mice received 
either 1 mg of 2A5 anti-Ibl0 antibody or 1 mg of GLl13 isotype control 
antibody intraperitoneally 1 h before LPS administration. Mice were then 
injected intraperitoneaUy with 400 #g LPS either alone, or concurrently 
with varying doses of Ibl0, as described in the Fig. 1 legend. Similar results 
were obtained in two separate experiments. 
with the LPS (Fig.  i  and Table  1). In most of these experi- 
ments, a substantial proportion of mice were protected after 
receiving 0.1 or 0.05 #g of Ibl0 at the time of LPS adminis- 
tration (Fig. 1 and Table 1). IL-10-mediated  protection of mice 
from lethal endotoxemia could be blocked by prior adminis- 
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Figure  3.  Ibl0 protects mice from lethal endotoxemia  when administered 
30 min after LPS injection. Groups of 20 BALB/c mice received 350/~g 
LPS intraperitoneally at time 0, and 1.0 #g rlL-10 intraperitoneally at ei- 
ther time 0, or 0.5, 1, 2, or 5 h after LPS injection. Animal survival was 
monitored over the following 7 d. 20 control mice receiving 350/~g LPS 
intraperitoneally in the absence of IL-10 all died in this experiment. Similar 
results were obtained in three separate experiments. 
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Figure 4.  IL-10  suppresses TNF-o~ release after LPS administration. 
Groups of 20 BALB/c mice were injected intraperitoneally  with either 
350 #g LPS (O), or 350 #g LPS concurrently with 1 #g of IL-IO (0). 
Sera were collected 1, 2, 3, and 4 h later, and assayed for TNF-oe content 
by ELISA. Each circle  represents  an individual  mouse. Similar  results  were 
obtained in three separate experiments. 
tration of neutralizing anti-I1-10  antibodies, but not by an 
isotype control antibody (Fig.  2), confirming the specificity 
of this effect. A kinetics study revealed that I1-10-mediated 
protection of mice from lethal endotoxemia was achieved even 
if the I1-10 was administered 30 min after the LPS injection 
(Fig. 3). However, further delays in II.-10 administration sub- 
stantially reduced protection, and no protection was observed 
when I1.10  was administered 5  h  after the LPS  injection 
(Fig.  3). 
Lethal endotoxemia is an undesirable monokine-mediated 
inflammatory reaction (3, 4). Since I1-10 has been shown to 
suppress monokine production by activated macrophages and 
monocytes in vitro (9,  10, 18, 19), we considered the possi- 
bility that  the above I1.10-mediated protection reflected a 
suppression of monokine production in the endotoxin-induced 
response. Indeed, sera collected 1,  2,  3,  and 4  h  after LPS 
+  I1.10  injection indicated a substantial reduction in cir- 
culating TNF-cr  levels in animals receiving LPS plus I1.10 
compared with animals receiving LPS alone (Fig.  4). Since 
anti-TNF antibodies similarly protect mice from lethal en- 
dotoxemia (3), it is likely that I1.10-induced suppression of 
TNF-cr  at least contributes to the protection this cytokine 
provides against lethal endotoxemia. Other properties ofi1.10 
may also contribute to this protection. In particular, in vitro 
studies have indicated that I1.10 also suppresses I1.1 produc- 
tion, and upregulates I1.1ra production, by activated macro- 
phages (9, 10, 21). Both of these consequences will presum- 
ably  also  contribute  to  protection  of mice  from  lethal 
endotoxemia in light of previously published reports showing 
the protective effects of direct I1.1ra  administration in this 
type of model (4). 
In summary, our data indicate that I1.10 is highly effective 
at protecting mice from lethal endotoxemia, a finding which 
suggests that I1-10 may be an important candidate for treat- 
ment of bacterial sepsis. Whereas numerous other reagents 
e.g., antibodies to TNF-o~ (3) or endotoxin (22-25), as well 
as the I1.1ra (4), are currently in clinical trials for treatment 
of bacterial sepsis, most of these need to be given before en- 
dotoxemia induction in animal model experiments in order 
to obtain optimal protection. One exception to this, the I1. 
lra, is effective when administered at the time of endotox- 
emia induction in animal model experiments, but must be 
administered in quantities large enough to block all endoge- 
nous I1.1 receptors (4). Since pharmacological doses of I1.10 
produce an array of effects on macrophage/monocyte func- 
tion that potentially will all contribute to protection from 
lethal endotoxemia, it  will be interesting to compare the 
efficacy of this cytokine versus  other current candidates in 
the treatment of bacterial sepsis. 
Table  2.  IL-IO Protects Mice from Death Resulting from Endotoxin-induced Shock 
No.  survivors/total mice 
IL-10/mouse  Expt.  1  2  3  4  5  6  7  Total 
~g 
0  4/20*  1/20  2/20  2/20  3/20  2.20~  1/20  15/140 
0.05  19/20  20/20  19/20  7/20  11/20  11/20  4/20  91/140 
0.1  20/20  20/20  20/20  15/20  16/20  16/20  13/20  120/140 
0.5  20/20  20/20  20/20  19/20  20/20  20/20  19/20  138/140 
1.0  20/20  20/20  20/20  20/20  20/20  20/20  20/20  140/140 
10  20/20  20/20  20/20  20./20  20/20  20/20  20/20  140/140 
" Mice in expts. 1-6 received 350 #g i.p.  LPS batch no.  1. 
* Mice in expts. 6 and 7 received 400 #g i.p. LPS batch no. 2. 
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